Oculis Holding AG

NASDAQ:OCS

11.7 (USD) • At close June 21, 2024
Bedrijfsnaam Oculis Holding AG
Symbool OCS
Munteenheid USD
Prijs 11.7
Beurswaarde 487,890,000
Dividendpercentage 0%
52-weken bereik 9.05 - 14.5
Industrie Biotechnology
Sector Healthcare
CEO Dr. Riad Sherif M.B.A., M.D.
Website https://oculis.com

An error occurred while fetching data.

Over Oculis Holding AG

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is

Vergelijkbare Aandelen

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)